MAPT and Alzheimer disease: Additionally, according to Wang's findings (2016), which indicated dysregulation of miR-146a contributed in tau hyperphosphorylation and AD pathogenesis63, we suggest that inhibition of this microRNA by QC treatment could be an in vivo novel therapy for cognitive disorders.